David R Martinez

List of Publications by Citations

47 papers	7,079 citations	26 h-index	55 g-index
55 ext. papers	10,304 ext. citations	27.1 avg, IF	5.7 L-index

#	Paper	IF	Citations
47	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*, **2020**, 369, 806-811	33.3	748
46	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. *Cell*, **2020**, 182, 429-446.e14	56.2	710
45	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *New England Journal of Medicine*, **2020**, 383, 1544-1555	59.2	612
44	Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature*, **2020**, 584, 443-449	50.4	609
43	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature*, **2020**, 586, 567-571	50.4	594
42	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science*, **2020**, 369, 812-817	33.3	592
41	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature*, **2020**, 586, 583-588	50.4	550
40	The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science Immunology*, **2020**, 5,	28	450
39	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. *Nature*, **2020**, 586, 560-566	50.4	299
38	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. *Nature Medicine*, **2020**, 26, 1422-1427	50.5	283
37	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *Cell Reports*, **2020**, 32, 107940	10.6	260
36	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *Journal of Experimental Medicine*, **2021**, 218,	16.6	171
35	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. *Science Translational Medicine*, **2021**, 13,	17.5	169
34	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science*, **2021**, 373, 1372-1377	33.3	150
33	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. *Cell*, **2021**, 184, 4203-4219.e32	56.2	89
32	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. *Nature*, **2021**, 594, 553-559	50.4	85
31	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. *Science*, **2021**, 373,	33.3	80

30	High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models. *Cell*, **2020**, 183, 429-441.e16	56.2	67
29	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness **2020**,		62
28	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 29832-29838	11.5	57
27	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. *Science*, **2021**, 373, 991-998	33.3	48
26	Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. *Journal of Virology*, **2021**,	6.6	40
25	Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. *MAbs*, **2020**, 12, 1778435	6.6	37
24	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. *Cell*, **2021**, 184, 5432-5447.e16	56.2	34
23	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates **2021**,		27
22	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. *DMM Disease Models and Mechanisms*, **2020**, 13,	4.1	26
21	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. *Science Translational Medicine*, **2021**, eabj7125	17.5	24
20	A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice **2021**,		24
19	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. *Cell Reports Medicine*, **2021**, 2, 100313	18	24
18	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. *Cell Reports*, **2021**, 36, 109450	10.6	23
17	Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. *Cell Reports*, **2020**, 33, 108226	10.6	13
16	Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants **2021**,		13
15	Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. *PLoS Pathogens*, **2020**, 16, e1008303	7.6	11
14	Chimeric spike mRNA vaccines protect against Sarbecoviru challenge in mice **2021**,		11
13	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. *MSphere*, **2021**, 6, e0027521	5	11

12	Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. *Nature*, **2021**,	50.4	9
11	Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice **2021**,		9
10	Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals **2021**,		8
9	Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. *Cell Host and Microbe*, **2020**, 27, 710-724.e7	23.4	7
8	Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions **2020**,		7
7	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.. *Science Translational Medicine*, **2022**, 14, eabm3410	17.5	7
6	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice **2021**,		5
5	Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses. **2022**,		3
4	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. *Journal of Virology*, **2021**, 95, e0097421	6.6	3
3	Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. *Cell Host and Microbe*, **2021**, 29, 13-22	23.4	3
2	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. **2022**,		2
1	Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.. *Journal of Virology*, **2022**, e0023122	6.6	